You are here

AstraZeneca shares plunge as the firm's lung cancer study fails

London

ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.

The so-called Mystic study was the most anticipated clinical experiment in the

sentifi.com

Market voices on:

Editor's Choice

Powered by GET.comGetCom